Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Design Therapeautics, Inc.
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Find out what a historical investment in Design Therapeautics, Inc. would be worth today using our DSGN stock calculator.
Market Capitalisation
$655.17M
Price-earnings ratio
-
Dividend yield
0.00%
Volume
2.5M
High today
$11.56
Low today
$10.31
Open price
$10.60
52-week high
$17.25
52-week low
$3.33
Ready to start your investing journey with Stake?
Open an accountHow do I buy DSGN shares in Australia?
Buying DSGN shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Design Therapeautics, Inc. in minutes.
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in DSGN
What is the ticker symbol of Design Therapeautics, Inc.?
The ticker symbol for Design Therapeautics, Inc. is DSGN.
How much is one share of DSGN?
One share of DSGN is valued at $11.14 as of 21 May 2026.
What is the market capitalisation of Design Therapeautics, Inc. DSGN?
As of 21 May 2026 Design Therapeautics, Inc. has a market cap of $655.17M.
What is the 52-week high for Design Therapeautics, Inc. stock?
The Design Therapeautics, Inc. 52-week high stock price is $17.25.
What is the 52-week low for Design Therapeautics, Inc. stock?
The Design Therapeautics, Inc. 52-week low stock price is $3.33.
Can I buy DSGN shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy DSGN shares and over 12,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in DSGN on Stake
- Buy DSGN from US$3 brokerage
- Invest in 9,500+ U.S. stocks and ETFs
- Own a slice of DSGN from only US$10 with fractional shares
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
DSGN related stocks